Multi-state Markov models in cancer screening evaluation: A brief review and case study

Statistical Methods in Medical Research

Volumn 19, Issue 5, 2010, Pages 463-486

  Uhry, Z ^a   Hedelin G ^b   Colonna, M ^c   Asselain, B ^d   Arveux, P ^e   Rogel, A ^a   Exbrayat, C ^f   Guldenfels, C ^g   Courtial, I ^h   Soler Michel, P ^h   Molinie F ⁱ   Eilstein, D ^a   Duffy, S W ^j  

^a INSTITUT DE VEILLE SANITAIRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Registre du Cancer de l'Isere   (France)

^d INSTITUT CURIE   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f Structure de Gestion du Dépistage de l'Isère   (France)

^g Structure de Gestion du Dépistage du Bas Rhin   (France)

^h Structure de Gestion du Dépistage du Rhône   (France)

ⁱ ETS de Loire Atlantique/Vendee   (France)

^j IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; HUMAN; LYMPH NODE METASTASIS; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL MODEL;

BREAST NEOPLASMS; HUMANS; LIKELIHOOD FUNCTIONS; MARKOV CHAINS; MASS SCREENING; MODELS, STATISTICAL;

EID: 77957796755     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280209359848     Document Type: Review

References (50)

1. Prorok PC Mathematical models for breast cancer screening. In Day NE, Miller AB, eds. Screening for breast cancer. Hans Huber, Toronto ; 1988: 95-109.
2. Walter SD, Day NE Estimation of the duration of a preclinical disease state using screening data. American Journal of Epidemiology 1983 ; 118: 865-886.
3. Day NE, Walter SD Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics 1984 ; 40: 1-14.
4. Stevenson CE Statistical model for cancer screening. Statistical Methods in Medical Research 1995 ; 4: 18-32.
5. Van Oortmarssen GJ, Boer R., Habbema JD Modelling issues in cancer screening. Statistical Methods in Medical Research 1995 ; 4: 33-54.
6. Duffy SW, Hill C., Estève J. Quantitative methods for the evaluation of cancer screening. Oxford University Press, New York ; 2001.
7. Boer R., Plevritis S., Clarke L. Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Statistical Methods in Medical Research 2004 ; 13: 525-538.
8. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine 2005 ; 353: 1784-1792.
9. Duffy SW, Chen HH, Tabar L., Day NE Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Statistics in Medicine 1995 ; 14: 1531-1543.
10. Chen HH, Duffy SW A Markov chain method to estimate the tumour progression rate from preclinical to clinical phase, sensitivity and positive predictive value for mammography in breast cancer screening. The Statistician 1996 ; 45: 307-317.
11. Duffy SW, Chen HH, Tabar L., Fagerberg G., Paci E. Sojourn time, sensitivity and positive predictive value of mammography screening for breast cancer in women aged 40-49. International Journal of Epidemiology 1996 ; 25: 1139-1145.
12. Chen HH, Duffy SW, Tabar L., Day NE Markov chain models for progression of breast cancer. Part I: tumour attributes and the preclinical screen-detectable phase. Journal of Epidemiology and Biostatistics 1997 ; 2: 9-23.
13. Chen HH, Duffy SW, Tabar L., Day NE Markov chain models for progression of breast cancer. Part II: prediction of outcomes for different screening regimes. Journal of Epidemiology and Biostatistics 1997 ; 2: 25-35.
14. Duffy SW, Day NE, Tabar L., Chen HH, Smith T. Markov models of breast tumor progression: some age-specific results. Journal of the National Cancer Institute, Monographs 1997 ; 22: 93-97.
15. Straatman H., Peer PGM, Verbeek ALM Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group. Biometrics 1997 ; 53: 217-229.
16. Chen HH, Thurfjell E., Duffy SW, Tabar L. et al. Evaluation by Markov chain models of a non-randomised breast cancer screening programme in women aged under 50 years in Sweden. Journal of Epidemiology and Community Health 1998 ; 52: 329-335.
17. Prevost TC, Rohan TE, Duffy SW, Chen HH, To T., Hill RD Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches. American Journal of Epidemiology 1998 ; 148: 609-619.
18. Chen TH, Kuo HS, Yen MF, Lai MS, Tabar L., Duffy SW Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 2000 ; 56: 167-172.
19. Chen TH, Yen MF, Lai MS, et al. Evaluation of a selective screening for colorectal carcinoma: the Taiwan Multicenter Cancer Screening (TAMCAS) project. Cancer 1999 ; 86: 1116-1128.
20. Myles JP, Nixon RM, Duffy SW, et al. Bayesian evaluation of breast cancer screening using data from two studies. Statistics in Medicine 2003 ; 22: 1661-1674.
21. Weedon-Fekjaer H., Vatten LJ, Aalen OO, Lindqvist B., Tretli S. Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results. Journal of Medical Screening 2005 ; 12: 172-178.
22. Weedon-Fekjaer H., Vatten LJ, Aalen OO, Lindqvist B., Tretli S. Estimating mean sojourn time and screening sensitivity using data on time since previous screening. Journal of Medical Screening 2008 ; 15: 83-90.
23. Chien CR, Lai MS, Chen TH Estimation of mean sojourn time for lung cancer by chest X-ray screening with a Bayesian approach. Lung Cancer 2008 ; 62: 215-220.
24. Yen MF, Tabár L., Vitak B., Smith RA, Chen HH, Duffy SW Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. European Journal of Cancer 2003 ; 39: 1746-1754.
25. Duffy SW, Agbaje O., Tabar L., et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Research 2005 ; 7: 258-265.
26. Olsen AH, Agbaje OF, Myles JP, Lynge E., Duffy SW Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program. Breast Journal 2006 ; 12: 338-342.
27. Weedon-Fekjaer H., Lindqvist BH, Vatten LJ, Aalen OO, Tretli S. Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Research 2008 ; 10: R41.
28. Shen Y., Zelen M. Parametric estimation procedures for screening programmes: stable and nonstable disease models for multimodality case finding. Biometrika 1999 ; 86: 503-515.
29. Shen Y., Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics 2005 ; 6: 604-614.
30. Pinsky PF Estimation and prediction for cancer screening models using deconvolution and smoothing. Biometrics 2001 ; 57: 389-395.
31. Pinsky PF An early- and late-stage convolution model for disease natural history. Biometrics 2004 ; 60: 191-198.
32. Cong XJ, Shen Y., Miller AB Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. Statistics in Medicine 2005 ; 24: 3123-3138.
33. Telesca D., Etzioni R., Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008 ; 64: 10-19.
34. van Oortmarssen GJ, Habbema JD, Lubbe JT, van der Maas PJ A model-based analysis of the HIP project for breast cancer screening. International Journal of Cancer 1990 ; 46: 207-213.
35. van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer 1990 ; 66: 1601-1612.
36. Loeve F., Boer R., van Oortmarssen GJ, van Ballegooijen M., Habbema JD The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Computers and Biomedical Research 1999 ; 32: 13-33.
37. van den Akker-van Marle ME, van Ballegooijen M., van Oortmarssen GJ, Boer R., Habbema JD Cost-effectiveness of cervical cancer screening: comparison of screening policies. Journal of the National Cancer Institute 2002 ; 94: 193-204.
38. Draisma G., Postma R., Schröder FH, van der Kwast TH, de Koning HJ Gleason score, age and screening: modeling dedifferentiation in prostate cancer. International Journal of Cancer 2006 ; 119: 2366-2371.
39. T Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R., Habbema JD The MISCAN-Fadia continuous tumor growth model for breast cancer. Journal of the National Cancer Institute Monographs 2006 ; 36: 56-65.
40. Arveux P., Wait S., Schaffer P. Building a model to determine the cost-effectiveness of breast cancer screening in France. European Journal of Cancer Care 2003 ; 12: 143-153.
41. Lejeune C., Arveux P., Fagnani F., Bonithon-Kopp C., Faivre J. A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer. European Journal of Cancer Prevention 2003 ; 12: 77-84.
42. Rodríguez-Moranta F., Trapero-Bertran M., Castells A., et al. Endoscopic requirements of colorectal cancer screening programs in average-risk population. Estimation according to a Markov model. Gastroenterologia Y Hepatologia 2008 ; 31: 405-412.
43. Jackson C., Sharples L., Thompson S., Duffy S., Couto E. Multistate Markov models for disease progression with classification error. Statistician 2003 ; 52: 193-209.
44. Venable WM and Ripley BD Modern Applied Statistics with S-Plus (3 rd edn). Springer-Verlag, New York ; 1999.
45. Paci E., Duffy SW Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975-1986). International Journal of Epidemiology 1991 ; 20: 852-858.
46. Brekelmans CT, Westers P., Faber JA, Peeters PH, Collette HJ Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) in The Netherlands: a comparison of different methods. Journal of Epidemiology and Community Health 1996 ; 50: 68-71.
47. Foucher Y., Giral M., Soulillou JP, Daures JP A flexible semi-Markov model for interval-censored data and goodness-of-fit testing. Statistical Methods in Medical Research 2008, doi: 10.1177/ 0962280208093889.
48. Foucher Y., Giral M., Soulillou JP, Daures JP A semi-Markov model for multistate and interval-censored data with multiple terminal events. Application in renal transplantation. Statistics in Medicine 2007 ; 26: 5381-5393.
49. Foucher Y., Mathieu E., Saint-Pierre P., Durand JF, Daurès JP A semi-Markov model based on generalized Weibull distribution with an illustration for HIV disease. Biometrical Journal 2005 ; 47: 825-833.
50. Castelli C., Combescure C., Foucher Y., Daures JP Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Statistics in Medicine 2007 ; 26: 5557-5571.